lipid modification
ApprovedSmall molecule
lipid modification is one of 49 small molecule programs targeting Combined hyperlipidemia. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Lopid
PfizerApproved
Selzentry
GSKApproved
Cipro
BayerApproved
Crestor
AstraZenecaApproved
Lovaza
AstraZenecaApproved
Topamax
WWim Janssens
Approved
Zocor
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zetia
OOrganon and Co
Phase 3
Statin
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertriglyceridemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lipid modification. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYonsei University